Equities Research Analysts’ upgrades for Tuesday, July 11th:

Aegion Corp (NASDAQ:AEGN) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “For 2017, Aegion expects higher revenues and operating income across all three platforms to result in solid earnings per share growth, greater cash generation and increasing ROIC. The company anticipates gross margins to expand in 2017 through consistent focus on labor utilization, project management and optimization of the fundamental business processes, along with a better year for turnaround support services. However, Aegion’s performance will be hurt by challenges in the Canadian upstream oil market due to low oil and gas prices. Other headwinds include escalating operating and interest expenses. Dismal condition of the U.S. water and wastewater infrastructure also remains a drag. Moreover, the stock underperformed the Zacks categorized sub industry over the past one year.”

Allergan PLC. (NYSE:AGN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $270.00 price target on the stock. According to Zacks, “Allergan is reshaping its portfolio through strategic acquisitions. Following the closure of the Teva deal, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Key products like Botox and Linzess and new products are supporting sales growth. Allergan’s share price has outperformed the broader industry, so far this year. It also boasts a strong pipeline. Biosimilars also represent significant opportunity. While we remain optimistic about the company’s growth prospects, it is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also new competition for key growth drivers, Restasis and Linzess, is an investor concern. Estimates have gone up ahead of the Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters.”

AMAG Pharmaceuticals (NASDAQ:AMAG) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $22.00 price target on the stock. According to Zacks, “AMAG has been pursuing strategic acquisitions and deals to boost its portfolio and pipeline. The company is making its investments in the launch of Intrarosa, expansion of the label for Feraheme, development work to support the bremelanotide NDA and expected approval and launch of the Makena subcutaneous auto-injector (SQ) . In June 2017, the FDA accepted the sNDA for the Makena subcutaneous auto-injector. The agency has established a Prescription Drug User Fee Act (PDUFA) target action date of Feb 14, 2018. AMAG is focused on expanding the Makena’s label further in a bid to increase its market share. AMAG’s shares have underperformed the Medical-Biomedical/Genetics industry year to date. The latest addition of Intrarosa and Rekynda will allow AMAG to address key needs of women’s healthcare.”

American Water Works (NYSE:AWK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $87.00 price target on the stock. According to Zacks, “Shares of American Water Works Company have outperformed the broader industry in the last six months. American Water Works’ continues to add customers and expand its market reach through acquisitions and organic growth. In addition, new water rates will also boost its performance. We expect the ongoing capital expenditure of the American Water Works’ to improve its water and wastewater systems, thereby allowing the company to provide efficient services to its expanding customer base. However, the company is subject to stringent regulations, fluctuating weather patterns and risk of accidents due to old and soiled pipelines.”

Boeing Company (The) (NYSE:BA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $228.00 price target on the stock. According to Zacks, “Boeing is the largest aircraft manufacturer in the world in terms of revenue, orders and deliveries, and one of the largest aerospace and defense contractors. Demand for its commercial airplanes is on the rise due to a steady improvement in passenger and freight traffic. Recently, the company released 20-year market outlook, as per which it forecasts jetliner demand to increase by 3.6%. The single-aisle jets are expected to be the major driver behind demand growth. Further, the company’s defense business stands out among its peers by virtue of its broadly diversified programs, strong order bookings and order backlog. Boeing’s share price has outperformed the Zacks categorized Aerospace/Defense industry price over the last one year. However, the company continues to face challenges from the uncertain fate of high-cost programs, order cancellations, stiff competition as well as falling delivery numbers.”

Calgon Carbon Corporation (NYSE:CCC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Calgon Carbon continues to grow through its product offerings and increased penetration into new and emerging end markets. It is also focused on cost cutting initiatives. The company should also gain from the acquisition of CECA’s assets. However, Calgon Carbon’s shares have underperformed the Zacks categorized Pollution Control industry over a year. The company’s industrial end-markets remain sluggish. Calgon Carbon is also seeing weak demand for activated carbon in specific markets. Uncertainties in the market are expected to sustain moving ahead. The company is also exposed to weakness in its ballast water treatment system business and currency headwinds.”

Century Aluminum Company (NASDAQ:CENX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $18.00 price target on the stock. According to Zacks, “Estimates for Century Aluminum for the second quarter have been going up lately. Century Aluminum has outperformed the Zacks categorized Metal Procurement & Fabrication industry over a year. Century Aluminum is implementing a number of actions to reduce costs and preserve cash amid a weak operating environment. It should also gain from strong aluminum demand across automotive and aerospace markets in its key regions, North America and China, as well as acquisitions. Moreover, the company has low debt and short-term obligations which will help it remain strong in an adverse environment.”

Celldex Therapeutics (NASDAQ:CLDX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $2.75 price target on the stock. According to Zacks, “Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer.  Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. “

Canadian National Railway Company (NYSE:CNI) (TSE:CNR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $93.00 price target on the stock. According to Zacks, “The improvement in the coal scenario is encouraging as headwinds pertaining to the commodity have been primarily responsible for the underperformance of Canadian National shares with respect to the Zacks categorized Transportation- Rail industry in the last one year. The stock has surged 36%, while the industry gained 37%. However, the stock has outperformed fellow railroad operator, Canadian Pacific, which has gained 20% over the last one year. We are also impressed by the company's initiatives to reward investors. Furthermore, the company's 2017 capital investment plan is a positive. The plan complements its efforts to promote safety and enhance productivity. Due to these tailwinds we expect the stock to perform well in the second quarter. Detailed results should be out on Jul 25. The Zacks Consensus Estimate has moved up 4.2% to $0.98 per share in the last month. The company's high debt levels, however, raise concerns.”

Corcept Therapeutics (NASDAQ:CORT) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Corcept is evaluating its most advanced candidate CORT125134 in a phase I/II study to treat patients with solid-tumor cancers. Corcept’s share price movement shows that the stock has outperformed the Zacks classified Medical-Drugs industry year to date. Notably, its efforts to expand Korlym’s label are encouraging and should boost the drug’s commercial potential significantly. However, Corcept is solely dependent on Korlym for growth. Therefore, a decline in Korlym sales will largely hinder the company’s growth prospects. But, the company is working on developing additional candidates, which are still years away from commercialization.”

CSX Corporation (NASDAQ:CSX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $61.00 target price on the stock. According to Zacks, “Shares of CSX Corporation have performed very well over the last one year, outperforming the Zacks-categorized Transportation-Rail industry. The company has outperformed fellow railroad operator Union Pacific Corporation that saw its shares gaining 18.7% in the last one year.  CSX Corporation is benefiting from an improvement in the coal-related scenario, which has been aiding overall volume growth. The company's efforts to control costs are also impressive.  CSX Corporation's move to hike its quarterly dividend payout as well as approving a new buyback plan also raise optimism. CSX aims to report operating ratio in the mid-60s by the end of 2017.  We expect the company to perform well in the second quarter. Detailed results should be out on Jul 18. The company's high debt levels, however, raise concerns. “

Connecticut Water Service (NASDAQ:CTWS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Shares of Connecticut Water Services returned higher than the Zacks categorized broader industry’s gain in the last twelve months. The company continues to strengthen its existing infrastructure through regular capital investments, which is a must in the water utility space. In addition, customer expansion in its service territories is boosting demand. However, Connecticut Water Services is subject to stringent environment regulations, demand variations with weather patterns, risk of water mains failure and contamination of water sources. “

Duke Energy Corporation (NYSE:DUK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $93.00 target price on the stock. According to Zacks, “Duke Energy’s hefty investment plans for the next five years, to improve its business by generating cleaner energy and bolstering its renewable asset base, buoys optimism. The acquisition of Piedmont Natural Gas is also expected to offer substantial boost to its business. Duke Energy also pursues a systematic asset divestment initiative. Moreover, it outperformed the Zacks categorized Utility-Electric Power industry over last one year. Duke Energy has also been pursuing additional generation projects, such as dual-fuel capabilities, and combined heat and power facilities to increase the flexibility of its system. Yet, stringent environmental regulations, severe weather patterns and foreign exchange risks may hinder Duke Energy’s performance.”

Horizon Pharma PLC (NASDAQ:HZNP) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Horizon’s results from the primary care business units was much below expectations in the first quarter due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. The company plans to overcome this underperformance by reducing certain costs in the primary care business unit in order to align its cost structure with the lower- than-expected sales. Due to the divestiture of Procysbi, the company now expects sales in 2017 to come around $985 million to $1.020 billion. On a positive note, Horizon is significantly increasing investments in one its key drugs, Krystexxa. Shares of the company have underperformed the Zacks classified industry.”

Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $136.00 price target on the stock. According to Zacks, “Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. A potential label expansion of the drug will further boost sales. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry in the last one year.”

IDEX Corporation (NYSE:IEX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $128.00 price target on the stock. According to Zacks, “In first-quarter 2017, IDEX witnessed record order levels and modest organic growth on a diligent execution of operational plans. IDEX is currently striving to expand its businesses in the emerging markets by focusing on a holistic growth model and actively balancing organic and inorganic growth. With a flexible yet disciplined focus on cost and productivity, the company expects to successfully tap newer markets to continuously boost its revenue. IDEX further intends to optimize its cost structure, increase its competitiveness and reallocate resources to improve its profitability. Management also raised its earlier guidance for 2017 on robust demand patterns and healthy growth dynamics. IDEX outperformed the industry year to date. However, IDEX’s performance is exposed to the frailties in the U.S. and international markets, while its acquisition spree often becomes a drag on the profitability.”

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $8.75 target price on the stock. According to Zacks, “Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters.”

International Paper Company (NYSE:IP) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $64.00 price target on the stock. According to Zacks, “International Paper is undergoing restructuring initiatives to transform itself into a core packaging company. It intends to invest $300 million through 2017 to further improve its North American containerboard mill system, enhance product quality, and reduce manufacturing and delivery costs. These projects are expected to have a collective internal rate of return of 20%. The acquisition of Weyerhaeuser’s pulp business is further likely to strengthen its position in the global fluff pulp market and augment operating cash flow. In addition, the company expects the acquisition to generate annual synergies of approximately $175 million by the end of 2018 along with a higher flexibility to manage a wide portfolio of products to meet customer needs through superior R&D capabilities and priceless patent portfolio. The company also outperformed the industry year to date. However, huge pension debt obligations erode its profitability.”

Impax Laboratories (NASDAQ:IPXL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $19.00 price target on the stock. According to Zacks, “Impax’s epinephrine auto-injector sales picked up and the company has 24 ANDAs pending FDA approval. Moreover, Impax’s generics pipeline should be able to take advantage of the upcoming patent expirations in the pharma industry. The acquisition of several generic products in Aug 2016 including 15 currently marketed products bode well for Impax. However, the Generics segment has been under competitive and pricing pressure, which is expected to persist through 2017. Meanwhile, the company is taking steps to reduce costs and improve efficiencies,which is expected to produce total savings of $130 million by the end of 2019. However, the company’s earnings guidance for 2017 is significantly lower than 2016 numbers as continued impact of lower pricing on generics is expected to dampen revenues.Estimates have remained mostly stable lately ahead of the Q2 results. Impax has a negative record of earnings surprises in the recent quarters.”

Juno Therapeutics (NASDAQ:JUNO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $32.00 price target on the stock. According to Zacks, “Juno remains on track with its pipeline candidates and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for the global development and commercialization of immunotherapies is encouraging. Juno’s shares outperformed the Medical-Biomed/Genetics industry so far this year. However, the company recently suffered a huge setback as it discontinued the development of cancer candidate, JCAR015 due to the toxicity witnessed in a phase II ROCKET study. Moreover, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters.”

CarMax (NYSE:KMX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $72.00 price target on the stock. According to Zacks, “CarMax has outperformed the Zacks-categorized Retail/Wholesale-Auto Parts industry in the last three months. Lately, both the quarterly and the yearly earnings estimates are moving up. CarMax’s focus on the used-car market helps it to outperform the industry. The company is among the strongest operators in its peer group. Also, its aggressive store-expansion is expected to benefit the company. Moreover, share repurchases will boost shareholder returns. However, the average selling prices in used vehicle as well as wholesale vehicle segment has been declining. The increase in the supply of used vehicles is expected to further lower prices.”

Kohl’s Corporation (NYSE:KSS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $41.00 target price on the stock. According to Zacks, “Although Kohl’s shares have underperformed the broader retail sector since the past six months due to difficult sales environment and lower comparable store sales, the company is making continuous efforts to improve its base business. The company prides on its strong brand portfolio and also commits to innovation, in order to keep the inventory assortment fresh and drive customer traffic to its stores and website. Lately, the company has started offering more outside famous brands and cutting down on the number of in-house clothing brands it sells. We note that strong inventory and expense management also led to year over year margin improvement during the first quarter of fiscal 2017. Although Kohl’s strategic initiative ‘Greatness Agenda’ is failing to deliver results in the near term, it remains optimistic regarding the plan to drive sales over the long term.”

Ligand Pharmaceuticals (NASDAQ:LGND) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Ligand’s Captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. However, the company derives a substantial portion of its revenues from royalties associated with the sales of two products – Promacta and Kyprolis. Any setback related to either of these two products could have a substantial impact on the company’s results. Notably, Ligand obtains Captisol from a single supplier. Hence any interruption in the supply of Captisol would have an adverse effect on the company’s results. Shares of Ligand have outperformed the broader industry in the last one year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters.”

ArcelorMittal (NYSE:MT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $26.00 price target on the stock. According to Zacks, “ArcelorMittal outperformed the Zacks categorized Steel-Producers industry over the past one year. ArcelorMittal should gain from its efforts to reduce debt, lower costs, expand capacity and improve efficiency. It is making a significant progress in its cost reduction initiatives under the Action 2020 program. Moreover, ArcelorMittal is looking to sell its non-core assets to focus on important operations and also expanding its advanced high strength steel product line.”

Nikon Corp (NASDAQ:NINOY) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $19.00 target price on the stock. According to Zacks, “Nikon’s growth blueprint is based on four initiatives — a merger & acquisition program, research & development program, human resource program and cost-reduction program. Nikon is focusing on expansion in two new segments, namely Medical and Instruments business. Also, Nikon is undertaking a number of initiatives to stabilize the key financials of its core business areas – including Precision Equipment and Imaging Products. Further, the company’s strategic acquisitions and investments to build its medical business is expected to help it reap significant benefits in the long-run. However, high R&D expenditure, restructuring costs and investments related to the medical business, are escalating the company’s operational costs, thus putting pressure on margins. Over the past year, Nikon’s shares underperformed the Zacks categorized Electronics – Manufacturing Machinery industry’s average.”

NRG Energy (NYSE:NRG) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $18.00 price target on the stock. According to Zacks, “NRG Energy is gaining from its asset drop-down program that is in sync with its long- term growth strategy. Its cost saving measures, providing power to a wide variety of customers, debt reduction plans and expansion of renewable operations should further drive growth. Since the company does not depend on a single customer to generate revenues, migration of customers to other operators does nothave anysignificant impact on the company’s earnings. Shares of NRG Energy have returned more than the broader industry in the last six months. However, stringent environmental regulations, restructuring of GenOn, fluctuating weather conditions and intense competition in the wholesale power markets are headwinds.”

Orexigen Therapeutics (NASDAQ:OREX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Orexigen’s sole marketed drug, Contrave, targets the obesity market which represents immense commercial potential. Contrave sales are picking up slowly. With the acquisition of U.S. rights of Contrave in Mar 2016 from Takeda, Orexigen has adopted a targeted approach for ramping up Contrave sales. Contrave should benefit from a more targeted sales effort. However, commercialization efforts have increased costs. We are also optimistic about the company’s collaboration agreement with several companies for the commercialization of the drug in Europe. The company’s shares underperformed the Zacks classified Medical/Biomedical Genetics industry in the last one year.  Meanwhile, Orexigen’s dependence on Contrave for growth and early stage of pipeline candidates remain potent concerns. Estimates have remained mostly stable lately ahead of the Q2 results. The company has a mixed record of earnings surprises in recent quarters.”

Petroleo Brasileiro S.A.- Petrobras (NYSE:PBR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $8.75 price target on the stock. According to Zacks, “Even though 2016 was a roller-coaster year for the energy market, Petrobras stock more than doubled during the period. The largest integrated energy firm in Brazil, Petrobras boasts of a healthy production growth and has announced several important discoveries of late. Additionally, loans from China should offer some relief considering Petrobras’ money-laundering scandal, which has scarred its credit metrics. Moreover, we appreciate the cost-control initiatives adopted by Petrobras. As it is, the company stands to benefit from Brazil’s economic growth and huge pre-salt oil reserves. Given its strong pipeline of development projects and impressive exploration successes, we recalibrate our investment thesis on Petrobras ADRs to 'Buy'..”

Packaging Corporation of America (NYSE:PKG) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Packaging Corporation anticipates second-quarter 2017 earnings of $1.45 per share, reflecting 16% year-over-year growth. It continues to implement its previously announced packaging segment price increases and expects higher corrugated products shipments in the second quarter. Energy costs are likely to improve as it enters into a seasonally milder weather. Moreover, the company will gain from acquisitions and its diverse product portfolio. The stock outperformed the Zacks categorized Containers-Paper/Plastic sub industry in the last one year. However, Packaging Corporation’s performance will be hurt by escalating expenses, continued price inflation on recycled fiber and strong competition.”

Quanta Services (NYSE:PWR) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Quanta Services began 2017 on a solid note, with robust year-over-year top- and bottom-line growth as well as an impressive revenues- and earnings-guidance hike for the full year. Going forward, the company expects a strong rebound in its end markets, including oil and gas, as it enters a renewed multiyear up-cycle for businesses. Also, rise in customers' multiyear capital budgets and favorable regulatory environment are expected to stoke growth. This apart, Quanta Services’ strategic acquisitions to boost core business holds promise. Despite these positives, over the past three months, shares of Quanta Services have significantly underperformed the Zacks categorized Engineering/R&D Services industry's return. The company believes that obtaining sighting and permission for energy infrastructure projects may continue to remain impact profitability. Also, project losses and delays, due to harsh weather conditions, add to woes.”

Gibraltar Industries (NASDAQ:ROCK) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “In the last one month, Gibraltar Industries' shares have outperformed the Zacks categorized Building & Construction Products Miscellaneous industry. The company intends to fortify its business on the back of unique innovations, ongoing 80/20 simplification process and new acquisitions. However, headwinds such as tepid end-market conditions, input price inflation, weaker volumes and backlogs are expected to hurt Gibraltar Industries' results in the upcoming quarters. For 2017, the company trimmed its earnings guidance to the $1.57-$1.70 per share range. Revenue is predicted to lie within the $970-$980 million range, down 2-3% year over year. Over the last 30 days, the Zacks Consensus Estimate for the stock remained unchanged for both 2017 and 2018.”

Rockwell Automation (NYSE:ROK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $184.00 target price on the stock. According to Zacks, “Rockwell Automation projects fiscal 2017 sales growth in the range of 4.5–7.5% and expects adjusted EPS in the range of $6.45–$6.75 per share. It remains optimistic about improvement in macro environment. Compared with earnings per share of $5.93 in fiscal 2016, the mid-point of the range depicts a year-over-year climb of 11%. Rockwell Automation will benefit from the consistent growth in the consumer and transportation verticals. It also expects heavy industries to grow in 2017 despite the prevailing softness in oil and gas and mining. Further, increased investment, acquisitions, product launches and share repurchases will support growth. Further, the company has a positive record of earnings surprises in recent quarters. Rockwell Automation's shares have outperformed the Zacks categorized sub-industry year-to-date.”

TherapeuticsMD (NASDAQ:TXMD) was upgraded by analysts at CIBC from a market perform rating to an outperform rating.

Receive News & Ratings for Aegion Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegion Corp and related companies with MarketBeat.com's FREE daily email newsletter.